Pharmacogenetics provides an opportunity for individualized drug selection and dosing. The question remains whether or not the cost of testing and phenotype identification provides optimal outcomes for the patient and opportunities for providers to more precisely target therapy. Lab companies have spent considerable time and money marketing genetic testing and the relevant clinical utility. This session will highlight the controversial nature of pharmacogenetic testing through a healthy debate of PROs and CONs. The audience will learn about updates on current evidence and practice contrasted with practical limitations. The debate is sure to be entertaining and informative, leaving the audience with a true perspective of both sides. (Recorded at PAINWeek 2017)
Did you enjoy this article?
Subscribe to the PAINWeek Newsletter
and get our latest articles and more direct to your inbox